Where AI Governance in Clinical Development Falls Short
A report in Applied Clinical Trials Online identifies gaps in how the clinical development industry governs its use of AI, suggesting that existing oversight frameworks are not keeping pace with how the technology is being deployed in drug and trial development.
Why this matters: Clinical trials sit at the intersection of sensitive health data and high-stakes medical decisions. When AI is used in that process without solid governance, the risks are not abstract. They affect which treatments get tested, who gets enrolled, and whether safety signals get caught in time. Weak oversight also means no clear answer when something goes wrong. Patients in trials rarely know AI was involved. They probably should.
Who should care: AI governance · Lawyers · Administrators · General readers · Policy
This summary is AI-assisted and may contain errors. It is an original briefing to help you gauge significance quickly — not a reproduction of the source. Always read the linked original before relying on it. See our methodology.